On March 22, 2007, the EMEA (European Medicines Agency), in its scientific committee CHMP (Committee for Medicinal Products for Human Use), has issued a positive opinion recommending the marketing authorisation for Revlimid.
Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma
EMP was founded in February 2006 in Vienna. The initiative came from patients of the six countries Austria, Belgium, Denmark, France, The Netherlands, and Switzerland.